Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
Source: View publication →
In an interim analysis of the phase 3 I CAN trial, the long-acting terminal complement C5 inhibitor ravulizumab significantly reduced proteinuria by 43.4% compared to placebo at 34 weeks in adults with IgA nephropathy on stable supportive care.
Key Findings
Study Design
Study Limitations
Clinical Significance
These findings establish that blocking the terminal complement pathway with ravulizumab yields a rapid and profound reduction in proteinuria for patients with IgA nephropathy at high risk of progression despite maximal supportive care (including RAAS and SGLT2 inhibitors). The robust 43.4% reduction in UPCR directly supported the FDA's accelerated approval of ravulizumab in October 2026, adding a potent, targeted biologic therapy to the expanding armamentarium of disease-modifying agents for IgA nephropathy.
Historical Context
Historically, the management of IgA nephropathy relied heavily on nonspecific blood pressure control using renin-angiotensin-aldosterone system (RAAS) inhibitors, with systemic corticosteroids reserved for high-risk patients. Recent insights into the pathogenesis of IgA nephropathy have highlighted the critical role of complement activation—specifically the alternative and terminal pathways—in driving glomerular inflammation and nephron loss. This paradigm shift has catalyzed the development of targeted therapies. Following the successes of targeted-release budesonide, dual endothelin-angiotensin receptor antagonists (sparsentan), and proximal complement inhibitors (iptacopan), the phase 3 I CAN trial confirms that downstream blockade of C5 cleavage by ravulizumab effectively attenuates kidney injury, marking a significant milestone in the precision management of glomerular diseases.
Guided Discussion
High-yield insights from every perspective
How does terminal complement inhibition with ravulizumab specifically target the pathophysiology of IgA nephropathy, given that it is classically considered an immune complex-mediated disease driven by galactose-deficient IgA1?
Key Response
IgA nephropathy is initiated by circulating galactose-deficient IgA1 immune complexes depositing in the mesangium. However, the subsequent severe tissue injury, inflammation, and glomerulosclerosis are heavily driven by activation of the alternative and lectin complement pathways. Ravulizumab binds C5, preventing its cleavage into C5a (a potent pro-inflammatory anaphylatoxin) and C5b (which initiates the Membrane Attack Complex, C5b-9). By blocking this terminal complement cascade, ravulizumab prevents complement-mediated endothelial and podocyte damage, reducing proteinuria.
When considering ravulizumab for a patient with progressive IgA nephropathy, what crucial prophylactic step must be taken prior to initiating therapy, and what existing supportive therapies should the patient already be optimized on?
Key Response
Before starting terminal complement inhibitors like ravulizumab, patients must receive meningococcal vaccination (and potentially prophylactic antibiotics depending on timing) due to the significantly increased risk of Neisseria meningitidis infection caused by C5 blockade. Additionally, reflecting the trial's enrollment criteria, patients should already be on maximally tolerated 'stable supportive care,' which primarily includes RAS inhibitors (ACEi/ARB) and, increasingly, SGLT2 inhibitors, before adding advanced disease-modifying agents.
The interim analysis of the I CAN trial demonstrates a significant 43.4% reduction in proteinuria at 34 weeks. Why is proteinuria accepted as an interim surrogate endpoint in IgAN trials, and how might upstream complement inhibition differ clinically from the terminal C5 inhibition seen with ravulizumab?
Key Response
Proteinuria reduction correlates strongly with long-term kidney survival in IgA nephropathy, leading the FDA to accept it as a reasonably likely surrogate endpoint for accelerated approval. Comparatively, terminal C5 inhibition leaves upstream complement opsonization (via C3b) intact, which preserves certain aspects of immune clearance but may leave upstream inflammatory mechanisms (like C3a-mediated signaling) unchecked in the glomerulus. Upstream inhibitors (e.g., targeting Factor B or C3) might offer broader blockade of alternative pathway activation but carry different infectious risk profiles.
With the emergence of multiple novel therapies for IgA nephropathy including targeted budesonide, endothelin receptor antagonists, and now terminal complement inhibitors, how should we phenotype high-risk patients to determine who benefits most from ravulizumab versus non-immunosuppressive agents?
Key Response
The therapeutic landscape for IgAN is shifting rapidly from non-specific blockade to targeted therapy. Attendings must phenotype patients using markers like biopsy acuity (Oxford MEST-C score, specifically endocapillary hypercellularity or crescents indicating active inflammation), trajectory of eGFR decline, and baseline proteinuria. Ravulizumab offers a targeted immune-modulating mechanism for patients with active, progressive, complement-driven inflammation, but requires IV infusions and carries infection risks, making it crucial to weigh against the hemodynamic benefits and oral convenience of agents like sparsentan or SGLT2 inhibitors.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In the phase 3 I CAN trial, an interim analysis was used to evaluate proteinuria reduction at 34 weeks for potential early regulatory submission. What are the statistical and methodological risks of unblinding trial data for interim surrogate outcomes regarding alpha-spending and the statistical power for the definitive hard endpoint of eGFR slope?
Key Response
Conducting an interim analysis requires complex alpha-spending functions (e.g., O'Brien-Fleming boundaries) to preserve the overall type I error rate for the final analysis. Unblinding for a surrogate endpoint like proteinuria introduces operational bias and reduces the alpha available for the final analysis. Furthermore, the trial must ensure that the early success on the surrogate endpoint does not compromise the retention of patients needed to achieve adequate statistical power to detect meaningful differences in the true clinical outcome, which is the long-term eGFR trajectory.
The trial compares ravulizumab to placebo in patients on 'stable supportive care.' Given the rapid evolution of standard-of-care in IgAN (e.g., widespread adoption of SGLT2 inhibitors), how might differential uptake of these new background therapies between the treatment and placebo arms confound the 34-week proteinuria endpoint?
Key Response
A rigorous critical appraisal must assess the 'moving target' of baseline standard of care in modern nephrology trials. If patients in the placebo arm had a disproportionately higher initiation or titration of SGLT2 inhibitors or ERAs during the trial as rescue or additive therapy, it could mask the efficacy of ravulizumab. Conversely, imbalanced background therapy favoring the intervention arm could artificially inflate the effect size. Ensuring and verifying balanced, truly 'stable' background care throughout the observation period is critical to the validity of the reported 43.4% reduction.
How does the 43.4% reduction in proteinuria achieved by ravulizumab influence potential updates to the KDIGO guidelines for IgA nephropathy, specifically regarding the sequencing of systemic immunosuppression versus novel targeted therapies for patients remaining at high risk despite optimized supportive care?
Key Response
Current KDIGO guidelines emphasize optimized RAS inhibition and suggest considering a 6-month course of glucocorticoids for patients with persistent proteinuria > 0.75-1.0 g/d, while explicitly warning about severe steroid-related toxicities. If ravulizumab is fully approved based on these compelling interim data and ultimately demonstrates eGFR preservation, guidelines will need to position complement inhibitors as a highly effective, steroid-sparing alternative. The committee must weigh the magnitude of proteinuria reduction and the safety profile (meningococcal risk vs. systemic steroid toxicity) to determine whether ravulizumab should replace steroids as a preferred advanced therapy.
Clinical Landscape
Noteworthy Related Trials
NefIgArd Trial
Tested
Nefecon (targeted-release budesonide) 16 mg daily
Population
Adults with primary IgAN at risk of progression
Comparator
Placebo
Endpoint
Time-weighted average change in eGFR over 2 years
PROTECT Trial
Tested
Sparsentan 400 mg daily
Population
Adults with IgAN and proteinuria despite maximal RAS inhibition
Comparator
Irbesartan 300 mg daily
Endpoint
Change in urine protein-creatinine ratio at 36 weeks
APPLAUSE-IgAN Trial
Tested
Iptacopan 200 mg twice daily
Population
Adults with primary IgAN and elevated proteinuria
Comparator
Placebo
Endpoint
Reduction in urine protein-creatinine ratio at 9 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis